Targeted liposomal doxorubicin/ceramides combinations: The importance to assess the nature of drug interaction beyond bulk tumor cells
Ana Filipa Cruz1,2, Nuno A. Fonseca1,3, Ana Rita Malheiro4,5, Joana B. Melo6,7, Maria Manuela Gaspar8, Rui Fernandes4,5, Vera Moura1,3, Sérgio Simões1,2, João Nuno Moreira1,2
1CNC – Center for Neurosciences and Cell Biology, Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Faculty of Medicine (Polo 1), Rua Larga, 3004-504 Coimbra, Portugal
2Univ Coimbra - University of Coimbra, CIBB, Faculty of Pharmacy, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
3TREAT U, SA - Parque Industrial de Taveiro, Lote 44, 3045-508 Coimbra, Portugal
4HEMS—Histology and Electron Microscopy, i3S-Instituto de Investigação e Inovação em Saúde, University of Porto, 4200-135 Porto, Portugal
5IBMC—Instituto de Biologia Molecular e Celular, University of Porto, 4200-135 Porto, Portugal
6iCBR—Coimbra Institute for Clinical and Biomedical Research, CIBB, Center of Investigation on Environment Genetics and Oncobiology (CIMAGO), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
7Univ Coimbra—University of Coimbra, Clinical Academic Center of Coimbra (CACC), Faculty of Medicine, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
8iMed.ULisboa, Research Institute for Medicines – Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
European Journal of Pharmaceutics and Biopharmaceutics
Tập 172
61-77
Thông tin tác giả